Preventing the Fatty Acid-Transporter CD36 From Taking its Toll on the Heart

HomeCirculation ResearchVol. 134, No. 5Preventing the Fatty Acid-Transporter CD36 From Taking its Toll on the Heart No AccessEditorialRequest AccessFull TextAboutView Full TextView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toNo AccessEditorialRequest AccessFull TextPreventing the Fatty Acid-Transporter CD36 From Taking its Toll on the Heart Mathias Mericskay Mathias MericskayMathias Mericskay Correspondence to: Mathias Mericskay, PhD, INSERM Laboratory of Signaling and Cardiovascular Pathophysiology UMR_S-1180, Faculty of Pharmacy, Paris-Saclay University, Orsay, France. Email E-mail Address: [email protected] https://orcid.org/0000-0002-6779-092X INSERM CARPAT Signalling and Cardiovascular Pathophysiology UMR_S-1180, Faculty of Pharmacy, Paris-Saclay University, Orsay, France. Originally published29 Feb 2024https://doi.org/10.1161/CIRCRESAHA.123.323945Circulation Research. 2024;134:526–528This article is a commentary on the followingGlycolysis-Mediated Activation of v-ATPase by Nicotinamide Mononucleotide Ameliorates Lipid-Induced Cardiomyopathy by Repressing the CD36-TLR4 AxisFootnotesFor Sources of Funding and Disclosures, see page 528.The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.Correspondence to: Mathias Mericskay, PhD, INSERM Laboratory of Signaling and Cardiovascular Pathophysiology UMR_S-1180, Faculty of Pharmacy, Paris-Saclay University, Orsay, France. Email mathias.mericskay@inserm.frREFERENCES1. Pandey A, LaMonte M, Klein L, Ayers C, Psaty BM, Eaton CB, Allen NB, de Lemos JA, Carnethon M, Greenland P, et al. Relationship between physical activity, body mass index, and risk of heart failure.J Am Coll Cardiol. 2017; 69:1129–1142. doi: 10.1016/j.jacc.2016.11.081CrossrefMedlineGoogle Scholar2. D'Souza K, Nzirorera C, Kienesberger PC. Lipid metabolism and signaling in cardiac lipotoxicity.Biochim Biophys Acta. 2016; 1861:1513–1524. doi: 10.1016/j.bbalip.2016.02.016CrossrefMedlineGoogle Scholar3. Piquereau J, Boitard SE, Ventura-Clapier R, Mericskay M. Metabolic therapy of heart failure: is there a future for B vitamins?Int J Mol Sci. 2021; 23:30. doi: 10.3390/ijms23010030CrossrefMedlineGoogle Scholar4. Wang S, Han Y, Liu R, Hou M, Neumann D, Zhang J, Wang F, Li Y, Zhao X, Schianchi F, et al. Glycolysis-mediated activation of v-ATPase by nicotinamide mononucleotide ameliorates lipid-induced cardiomyopathy by repressing the CD36-TLR4 axis.Circ Res. 134:505–525. doi: 10.1161/CIRCRESAHA.123.322910LinkGoogle Scholar5. Liu Y, Steinbusch LKM, Nabben M, Kapsokalyvas D, van Zandvoort M, Schönleitner P, Antoons G, Simons PJ, Coumans WA, Geomini A, et al. Palmitate-induced vacuolar-type H+-ATPase inhibition feeds forward into insulin resistance and contractile dysfunction.Diabetes. 2017; 66:1521–1534. doi: 10.2337/db16-0727CrossrefMedlineGoogle Scholar6. Glatz JFC, Heather LC, Luiken JJFP. CD36 as a gatekeeper of myocardial lipid metabolism and therapeutic target for metabolic disease.Physiol Rev. 2023; doi: 10.1152/physrev.00011.2023CrossrefMedlineGoogle Scholar7. Wang S, Schianchi F, Neumann D, Wong L-Y, Sun A, van Nieuwenhoven FA, Zeegers MP, Strzelecka A, Col U, Glatz JFC, et al. Specific amino acid supplementation rescues the heart from lipid overload-induced insulin resistance and contractile dysfunction by targeting the endosomal mTOR-v-ATPase axis.Mol Metab. 2021; 53:101293. doi: 10.1016/j.molmet.2021.101293CrossrefMedlineGoogle Scholar8. Mericskay M. Nicotinamide adenine dinucleotide homeostasis and signalling in heart disease: pathophysiological implications and therapeutic potential.Arch Cardiovasc Dis. 2016; 109:207–215. doi: 10.1016/j.acvd.2015.10.004CrossrefMedlineGoogle Scholar9. Bhasin S, Seals D, Migaud M, Musi N, Baur JA. Nicotinamide adenine dinucleotide in aging biology: potential applications and many unknowns.Endocr Rev. 2023; 44:1047–1073. doi: 10.1210/endrev/bnad019CrossrefMedlineGoogle Scholar10. Diguet D, Trammell S, Tannous C, Deloux R, Piquereau J, Mougenot N, Gouge A, Gressette M, Manoury B, Blanc J, et al. Nicotinamide riboside preserves cardiac function in a mouse model of dilated cardiomyopathy.Circulation. 2018; 137:2256–2273. doi: 10.1161/CIRCULATIONAHA.116.026099LinkGoogle Scholar11. Fletcher RS, Ratajczak J, Doig CL, Oakey LA, Callingham R, Da Silva Xavier G, Garten A, Elhassan YS, Redpath P, Migaud ME, et al. Nicotinamide riboside kinases display redundancy in mediating nicotinamide mononucleotide and nicotinamide riboside metabolism in skeletal muscle cells.Mol Metab. 2017; 6:819–832. doi: 10.1016/j.molmet.2017.05.011CrossrefMedlineGoogle Scholar12. Lu M, Ammar D, Ives H, Albrecht F, Gluck SL. Physical interaction between aldolase and vacuolar H+-ATPase is essential for the assembly and activity of the proton pump*.J Biol Chem. 2007; 282:24495–24503. doi: 10.1074/jbc.m702598200CrossrefMedlineGoogle Scholar13. Chan C-Y, Dominguez D, Parra KJ. Regulation of vacuolar H+-ATPase (V-ATPase) reassembly by glycolysis flow in 6-phosphofructo-1-kinase (PFK-1)- deficient yeast cells.J Biol Chem. 2016; 291:15820–15829. doi: 10.1074/jbc.M116.717488CrossrefMedlineGoogle Scholar14. Yagi M, Do Y, Hirai H, Miki K, Toshima T, Fukahori Y, Setoyama D, Abe C, Nabeshima Y-I, Kang D, et al. Improving lysosomal ferroptosis with NMN administration protects against heart failure.Life Sci Alliance. 2023; 6:e202302116. doi: 10.26508/lsa.202302116CrossrefMedlineGoogle Scholar15. Damgaard MV, Treebak JT. What is really known about the effects of nicotinamide riboside supplementation in humans.Sci Adv. 2023; 9:eadi4862. doi: 10.1126/sciadv.adi4862CrossrefMedlineGoogle Scholar16. Song Q, Zhou X, Xu K, Liu S, Zhu X, Yang J. The safety and antiaging effects of nicotinamide mononucleotide in human clinical trials: an update.Adv Nutr. 2023; 14:1416–1435. doi: 10.1016/j.advnut.2023.08.008CrossrefMedlineGoogle Scholar eLetters(0)eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.Sign In to Submit a Response to This Article Previous Back to top Next FiguresReferencesRelatedDetailsRelated articlesGlycolysis-Mediated Activation of v-ATPase by Nicotinamide Mononucleotide Ameliorates Lipid-Induced Cardiomyopathy by Repressing the CD36-TLR4 AxisShujin Wang, et al. Circulation Research. 2024;134:505-525 March 1, 2024Vol 134, Issue 5 Advertisement Article InformationMetrics © 2024 American Heart Association, Inc.https://doi.org/10.1161/CIRCRESAHA.123.323945PMID: 38422178 Originally publishedFebruary 29, 2024 KeywordsEditorialscardiomyopathies, secondaryendocytosisheart failurelipid metabolismobesityPDF download Advertisement